Eric Venker, President and Immunovant CEO of Roivant Sciences Ltd. (ROIV), divested 200,000 shares of the company's stock on March 17, 2026. The transactions, executed at an average price of $28.24 per share, amounted to approximately $5.65 million.
This sale by a key executive follows a series of other significant sell-offs by Roivant Sciences insiders in recent weeks. While insider selling can occur for a variety of reasons, including personal financial planning and diversification, such transactions are closely monitored by the market for any potential shifts in executive sentiment.